Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: Systematic review
BMJ Oct 11, 2018
Matthews A, et al. - In women with a history of non-metastatic breast cancer, researchers examined the impact of endocrine therapies on a wide range of specific clinical cardiovascular disease outcomes. The totality of the randomized controlled trial and observational evidence suggested an increased risk of venous thromboembolism in tamoxifen users vs both non-users and aromatase inhibitor users. Data also indicated a higher risk of vascular diseases, myocardial infarction, and angina in aromatase inhibitor users vs tamoxifen users, which might be driven by a protective effect of tamoxifen.
Sign-up to continue reading. It is free & takes less than 2 mins
45 lakhs+ doctors trust M3 globally
Free & unlimited access to original articles and quizzes
Secure: we never sell your data
Sign up with M3 India to try daily quizzes and take part in competitionsTry M3 India / Log In
Why join our Market Research Panel?
- 10K+ Doctors participated in 40+ Indian and Global studies in 2018
- Average honorarium per study was Rs. 1,600 and total honoraria as high as Rs. 12,000 was earned by a Doctor